Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a clinical-stage biotechnology company dedicated to developing immune-modulating therapies for life-threatening conditions. The company's main focus lies in targeting the CD40L pathway, aiming to provide novel treatments for organ and cellular transplantation, autoimmune diseases, and neurodegenerative conditions.
At the core of Eledon's research is tegoprubart, a humanized IgG1 anti-CD40L antibody. Tegoprubart shows high affinity for CD40 Ligand (CD40L), a crucial biological target involved in generating pro-inflammatory responses in autoimmune diseases, transplant rejection, and neuroinflammation. The CD40/CD40L pathway is essential in both adaptive and innate immune responses, making it a prime target for non-lymphocyte depleting therapeutic interventions.
In 2023, Eledon achieved significant milestones, including presenting initial clinical evidence of tegoprubart's potential to prevent organ rejection while maintaining robust kidney function and a favorable safety profile. The company also played a pivotal role in the second-ever genetically modified heart transplant from a pig to a human, using tegoprubart as a key immunosuppressive component.
Looking forward to 2024, Eledon is committed to advancing its clinical programs. Key initiatives include ongoing development in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). The firm has several pivotal studies underway, including a Phase 1b trial for kidney transplantation, a long-term safety and efficacy extension study, and the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus in kidney transplant patients.
Financially, Eledon reported a net loss of $40.3 million for 2023, slightly improved compared to the previous year's $88.0 million, which included a significant non-cash goodwill impairment charge. The firm's research and development expenses increased to $30.3 million, underscoring its commitment to advancing its clinical pipeline.
Eledon Pharmaceuticals is headquartered in Irvine, California, and continually seeks to build on its deep historical knowledge of anti-CD40L biology to develop groundbreaking therapies. For more information, visit www.eledon.com.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced participation in two virtual investor conferences. The LifeSci Partners Corporate Access Event will be held from January 5-7, 2022, featuring 1x1 meetings. The second event, H.C. Wainwright BIOCNNECT Virtual Conference, is scheduled for January 10-13, 2022 with available on-demand presentations and 1x1 meetings. Eledon focuses on developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative conditions, led by its compound AT-1501, targeting the CD40 ligand pathway.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q3 2021 financial results, marking a net loss of $9.8 million or $0.66 per share, an increase from the previous year's loss of $6.1 million. The company is progressing with its AT-1501 treatment, nearing full enrollment in its Phase 2 ALS study and receiving FDA IND clearance for islet cell transplantation. A collaboration with CareDx was also announced to enhance renal transplantation research. With approximately $94 million in cash, Eledon is funded into 2023 and anticipates key clinical developments in the upcoming quarters.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced a presentation by CEO David-Alexandre C. Gros on November 5, 2021, during the virtual Transplant Innovation Day hosted by CareDx. The focus will be on the investigational use of AT-1501 for kidney transplantation and its collaboration with CareDx to evaluate efficacy in preventing organ rejection. Eledon leverages CareDx’s advanced technologies, including the KidneyCare™ suite, to enhance data collection on allograft health as part of its clinical development efforts.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced participation in two virtual investor conferences in November. The first is the Guggenheim 3rd Annual Neuro/Immunology Conference on November 15-16, followed by the Jefferies London Healthcare Conference on November 18-19, featuring available on-demand presentations. Eledon focuses on developing targeted therapies for autoimmune diseases and organ transplants, with its lead compound, AT-1501, an anti-CD40L antibody aimed at immune regulation and potentially superior safety and efficacy.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its financial results for Q3 2021 on November 11, after market close. The management team will host a conference call and webcast at 4:30 PM ET to discuss the results. Eledon is focused on developing targeted therapies for autoimmune diseases and ALS, with its lead compound, AT-1501, targeting the CD40L pathway. This humanized IgG1 antibody aims to improve safety and dosing advantages compared to existing therapies. The webcast will be archived for one year after the event.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced its participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) on October 7, 2021. Dr. Steve Perrin, the company's President and Chief Scientific Officer, will engage in a panel discussing ALS clinical trial design. Additionally, Eledon will present a poster on the Phase 2 study of AT-1501, their lead compound targeting CD40L for conditions including ALS. The company focuses on developing therapies for autoimmune diseases and transplant patients, aiming to improve safety and efficacy in treatment.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on autoimmune diseases and organ transplants, announced an upcoming presentation on its lead candidate AT-1501 at the IPITA Congress, taking place virtually from October 20-23, 2021. The oral presentation, titled Use of Novel Antibodies/Mechanisms for Achieving Islet Transplantation Tolerance, will showcase pre-clinical data on AT-1501's effectiveness in preventing islet allograft rejection in nonhuman primate models. The session is scheduled for October 22 at 9:50 AM EST.
Eledon Pharmaceuticals (ELDN), a clinical stage biopharmaceutical company, announced upcoming presentations at major healthcare conferences. Management will present on-demand at the HC Wainwright 23rd Annual Global Investment Conference starting on September 13, 2021, at 7:00 AM EST. Additionally, a corporate overview will be presented at the Cantor Global Healthcare Conference on September 30, 2021, at 3:20 PM EST. The presentations can be accessed for 90 days post-event on the company's website. Eledon focuses on developing targeted medicines for patients with autoimmune diseases and ALS.
Eledon Pharmaceuticals announced significant progress in developing AT-1501 for kidney transplantation, receiving a No Objection Letter from Health Canada to initiate a clinical trial and agreeing with the FDA on a preclinical study involving non-human primates. The company also plans to develop AT-1501 for IgA nephropathy, with a Phase 2 trial set to begin by the end of 2021. Financially, Eledon reported a net loss of $7.4 million for Q2 2021, up from a loss of $2.6 million the previous year, with a cash balance of $101.1 million.
Eledon Pharmaceuticals (NASDAQ: ELDN) will report its financial results for Q2 2021 on August 12, after market close. A conference call and webcast will be held at 4:30 PM ET the same day. Eledon focuses on developing targeted therapies for autoimmune diseases and conditions requiring organ transplants, as well as ALS. Its lead candidate, AT-1501, targets the CD40L pathway, which has shown promise in improving treatment safety and efficacy. More information can be found on Eledon's website.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
What does Eledon Pharmaceuticals specialize in?
What is tegoprubart?
What are the recent achievements of Eledon Pharmaceuticals?
What are Eledon Pharmaceuticals' financial highlights for 2023?
Where is Eledon Pharmaceuticals headquartered?
What clinical trials are currently underway at Eledon Pharmaceuticals?
How does tegoprubart work?
What is the significance of the CD40/CD40L pathway?
What are the future plans for Eledon Pharmaceuticals?
How can I learn more about Eledon Pharmaceuticals?
